Novo Nordisk A/s

Jeppe Sturis

Helle Birk Olsen

Peter Madsen

Thomas Boerglum Kjeldsen

Frantisek Hubalek

Mathias Norrman

Svend Havelund

Ulla Ribel-Madsen

Jesper F Lau

Henrik Bengtsson

Thomas Kruse Hansen

Kjeld Madsen

Nils Langeland Johansen

Svend Ludvigsen

Thomas Børglum Kjeldsen

Lars Eilertsen

Morten Schlein

Jonas Kildegaard Pedersen

Helle Naver

Birgitte Koch Michelsen

Rikke Bjerring Andersen

Kezia A Juul

Karen-Margrethe Pedersen

Ulla Ribel

The invention concerns a soluble insulin preparation comprising NϵB29-hexadecandioyl-γ-Glu-(desB30) human insulin in a concentration from 1800 nmol/ml to 4200 nmol/ml, Zinc ions in a concentration from 4.0 Zn/6Ins to 7.0 Zn/6Ins, Niacinamide in a concentration from 110 mM to 220 mM or treprostinil in a concentration from 0.02 μg/ml to 1 μg/ml, Citrate in a concentration from 6 mM to 40 mM, and pH in the range from 7.0 to 8.0. The invention further comprises a method for using the soluble insulin preparation for reducing the blood glucose level in a mammal and a process for preparing the soluble insulin preparations.

High concentration insulin formulation

The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.

Insulin analogues and uses thereof

Novel GLP-1 compounds and their therapeutic use.

GLP-1 compounds

A drug delivery assembly includes a housing (), a piston () axially displaceable in the housing, and a variable volume reservoir () formed by the housing and the piston and containing a fluid first drug. The assembly further includes an exterior fluid inlet () arranged in or configured to be arranged in fluid communication with the reservoir, a fluid outlet () arranged in or configured to be arranged in fluid communication with the reservoir, biasing means () configured for moving the piston forwards, and releasable retaining means () configured for retaining the piston in an initial position, whereby the biasing means is allowed to move the piston forwards to expel fluid drug from the reservoir when the retaining means is released.

Drug filled delivery assembly

Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.

Preparation comprising insulin, nicotinamide and an amino acid

Growing community of inventors

Vaerloese, Denmark

Jeppe Sturis